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Abstract
Background: Cancer-related fatigue (CRF) and insomnia are major complaints in breast cancer survivors (BC).
Aerobic training (AT), the standard therapy for CRF in BC, shows only minor to moderate treatment effects. Other
evidence-based treatments include cognitive behavioral therapy, e.g., sleep education/restriction (SE) and
mindfulness-based therapies. We investigated the effectiveness of a 10-week multimodal program (MT) consisting
of SE, psycho-education, eurythmy- and painting-therapy, administered separately or in combination with AT (CT)
and compared both arms to AT alone.
Methods: In a pragmatic comprehensive cohort study BC with chronic CRF were allocated randomly or by patient
preference to (a) MT, (b) CT (MT + AT) or (c) AT alone. Primary endpoint was a composite score of the Pittsburgh
Sleep Quality Index and the Cancer Fatigue Scale after 10 weeks of intervention (T1); a second endpoint was a
follow-up assessment 6 months later (T2). The primary hypothesis stated superiority of CT and non-inferiority of MT
vs. AT at T1. A closed testing procedure preserved the global α-level. The intention-to-treat analysis included
propensity scores for the mode of allocation and for the preferred treatment, respectively.
Results: Altogether 126 BC were recruited: 65 were randomized and 61 allocated by preference; 105 started the
intervention. Socio-demographic parameters were generally balanced at baseline. Non-inferiority of MT to AT at T1
was confirmed (p < 0.05), yet the confirmative analysis stopped as it was not possible to confirm superiority of CT
vs. AT (p = 0.119). In consecutive exploratory analyses MT and CT were superior to AT at T1 and T2 (MT) or T2 alone
(CT), respectively.
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Conclusions: The multimodal CRF-therapy was found to be confirmatively non-inferior to standard therapy and
even yielded exploratively sustained superiority. A randomized controlled trial including a larger sample size and a
longer follow-up to evaluate multimodal CRF-therapy is highly warranted.
Trial register: DRKS-ID: DRKS00003736. Recruitment period June 2011 to March 2013. Date of registering 19 June
2012.
Keywords: Aerobic training, Anthroposophic medicine, Cognitive behavior therapy, Breast cancer, Cancer-related
fatigue, Eurythmy therapy, Multimodal intervention, Painting therapy, Sleep education, Sleep restriction
Background
Cancer-related fatigue (CRF) is a major issue in cancer pa-
tients. In a British study 58% of all cancer outpatients re-
port fatigue to affect them ‘somewhat to very much’,
therewith denoting it as the most important yet insuffi-
ciently treated symptom burden [1]. CRF is defined as ”a
distressing, persistent, subjective sense of physical, emo-
tional and/or cognitive tiredness or exhaustion related to
cancer or cancer treatment that is not proportional to re-
cent activities and interferes with usual functioning…“ [2].
Apart from tumor disease and burden, CRF is mainly
caused by chemo-, radio and possibly anti-hormonal
treatment [2]. A new study reports high fatigue levels to
be associated with gene polymorphism causing a high
expression in promoter regions of three different interleu-
kins (IL1B, IL6, TNF alpha) [3]. Sleep disorders, particu-
larly insomnia, psychological distress or further chronic
internal medical conditions constitute modulating and ag-
gravating factors [4]. In 34% of breast cancer survivors
CRF persists after 5 to 10 years [5], and global and cogni-
tive fatigue are still captured after 10.6 years in 17 and
28% of patients, respectively [6]. In this population CRF is
a frequent reason for invalidity pensions in Germany [7].
The treatment of CRF with the best available evidence in
breast cancer is aerobic training, showing a minor to mod-
erate (standardized mean-differences) effect size of 0.27 to
0.315 [8, 9]. Cognitive behavioral approaches such as
psycho-education yield minor effect sizes [9], while sleep
educational approaches including sleep-restriction and
stimulus control [10, 11] show minor to moderate effect
sizes comparable with mindfulness-based interventions
[12, 13]. For pharmacological therapies the evidence is still
unclear [14] even though some authors have recom-
mended stimulants such as Ritalin or Modafinil in case of
severe fatigue [15]. Another pharmacological approach is
mistletoe treatment, for which positive results in the re-
duction of fatigue have been published; trials using suffi-
ciently robust fatigue measures with CRF as primary
outcome are still lacking [16].
Due to the difficulty in CRF treatment and the unsatisfac-
tory results of mono-therapies a multidisciplinary therapy
appears to be a more appropriate approach [17] with
slightly better effect-sizes on fatigue for a combined aerobic
training and myofascial release massage compared to the
above cited meta-analysis for aerobic training alone (mod-
erate effect-sizes = 0.52) and significantly better than usual
care [18]. Therefore, we developed a 10-week inter-
vention program based on Anthroposophic Medicine
[19] including psycho-education, sleep-education, a
mindfulness-oriented movement therapy (eurythmy
therapy) and painting therapy which significantly im-
proved CRF in a pilot study, and sleep quality and
autonomic regulation [20]. In this paper we report on
a trial comparing the multimodal (sleep-education,
psycho-education, eurythmy, and painting therapy)
therapy and a combination of multimodal and aerobic
treatment with the standard therapy, i.e., aerobic
training only.
Methods
A prospective, parallel, open-label pragmatic trial was
conducted in three centers, the 1) Research Institute
Havelhöhe and Department of Internal Medicine, Hospital
Havelhöhe, Berlin, 2) Center of Integrative Medicine, Uni-
versity Witten/Herdecke and Department of Gynecology,
Hospital Witten/Herdecke, and 3) in the Department of
Rehabilitation Medicine, Hannover Medical School, all
located in Germany, from June 2011 to December 2013.
The study had a comprehensive cohort design, i.e., pa-
tients could decide if the study intervention was chosen
based on their own preference or by randomization.
The study was an investigator initiated trial, conducted
according to the declaration of Helsinki, approved by
the responsible local ethics committees and subject to
GCP-conform on-site monitoring. The trial is registered
in the German register of clinical studies (DRKS-ID:
DRKS00003736).
Patients
Most patients were recruited through local newspapers
and through physicians who informed their patients of
our study; other patients spontaneously contacted the
study centers. All participants signed an informed con-
sent form after the study had been explained to them.
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Patients were eligible if they were female breast cancer
patients between 18 and 75 years old, had a diagnosis of
chronic Cancer-related Fatigue for more than 6 months
(Fatigue Numerical Scale ≥ 4 and Cancer Fatigue Scale
(CFS-D ≥ 24)), a history of at least 36 months since
surgery/the end of adjuvant (radio-) chemotherapy and a
maximum of 45 months after first diagnosis. Exclusion
criteria are listed in Table 1.
Treatment allocation and randomization
All patients received information about the study design
and study interventions to support them in their decision
to be allocated to one of the intervention groups based on
their own preference or by randomization. Balanced
randomization lists (i.e., group proportions of 1:1:1) with
varying permutation block sizes were separately created
for each center beforehand. The randomized allocation
was conducted by a central randomization service via fax
at the Institute for Clinical Research, Berlin. No conceal-
ment of treatments was carried out.
Procedure and intervention
The study interventions, multimodal therapy (MT) and the
multimodal-aerobic combination therapy (CT) were devel-
oped at the Research Institute Havelhöhe, Berlin, defined
in an intervention manual resulting from a consensus
process involving a group of experts (internists, oncolo-
gists, specialists in sleep medicine, psycho-oncologists,
physio-, painting-, and eurythmy therapists) [21] and tested
for feasibility in a pilot-study [20].
After capturing baseline measurement (T0) the outcome
parameters were to be evaluated after an intervention
period of 10 weeks (T1) and a subsequent follow up
period of 6 months (T2) (Fig. 1).
MT was to be carried out with an intensity of 140–
165 min per week and an additional 15 min for debrief-
ing. According to protocol, the intervention was planned
to take a total of 1450 min over 10 weeks. In CT the
length of therapy was to be 165–185 min with an add-
itional 15-min period for debriefing. The intervention
took a total of 1810 min over a 10-week period.
Psycho-education (MT/CT)
Following a feedback procedure at the beginning of each
session the psycho-oncologist gave information on, and
highlighted the understanding of illness, processing of ill-
ness and dealing with distressing feelings and thoughts,
promotion of mental and physical health, social support
and communication, personal responsibility, inner con-
centration exercises, stress management, and issues of
reorientation [22]. After each session the participants were
given exercises to be carried out until the next psycho-
education session.
Sleep education (MT/CT)
Patients attended an information session on the basics
of chronobiology and sleep. This education aimed to
contribute towards an improved understanding of sleep,
and therefore also consecutively to an improvement in
the ability to self-manage sleep problems and the
stabilization of day and night sleep hygiene. Patients
were also asked to fill out a sleep diary, once prior to the
start of the intervention and a second time after two in-
dividual adjustments of the sleep rhythm in accordance
to the sleep-restriction and stimulus protocol recom-
mendations [23, 24].
Eurythmy therapy (MT/CT)
Eurythmy therapy is a mindfulness-based movement
therapy used in anthroposophic medicine for more than
90 years which expresses sounds and rhythms as move-
ments and gestures [25]. The following exercises, such
as I-A-O, clenching-spreading, striding, rhythms/hexam-
eter, the vowel”Ei“, and consonants which should achieve
a rhythmic stabilisation such as L, M, and R, were prac-
tised for the improvement of breast cancer-related
dysrhythmia [26]. The so-called ”cancer series“ O-E-M-
L-EI-B-D was also introduced and practised [20, 25].
Each session was followed by a rest period of 15 min.
Painting therapy (MT/CT)
Painting therapy was implemented in Anthroposophic
Medicine by Margaretha Hauschka [27]. Its aim is to
stimulate the cognitive and affective functions [20]. Each
Table 1 Exclusion criteria
• metastases,
• (radio-)chemotherapy or surgery in the last 6 months,
• anemia (hemoglobin <10 mg/dl),
• other severe chronic conditions:
- heart insufficiency > NYHA 1°,
- instable angina pectoris > NYHA 1,
- peripheral arterial occlusive disease > stage 1,
- COPD > stage 2,
- chronic renal insufficiency (creatinine > 2,5 mg/dl),
- manifest non-treated hypothyreosis (TSH > 4 mU/l, fT4 < 9 pmol/l)
or hyperthyreosis (TSH <4 mU/l, fT4 > 24 pmol/l),
- severe limitations of musculoskeletal system,
- manifest major-depression or psychosis,
- sleep-disorders such as untreated sleep apnea syndrome,
- untreated relevant restless legs-syndrome or narcolepsy,
• ongoing erythropoietin-therapy or transfusions,
• intensive training with optimized physical training of more than
2 × 30 min per week,
• psychotherapy started within the last 3 months or specified
CRF-education or sleep education within the last year.
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therapy session started with a 10-min period where pa-
tients were asked to draw shapes. Then patients were
asked to produce a series of paintings with a rhythmic
development of day/night motifs and a light/darkness
spectrum using water colors, starting with a painting in
blue and the gradual reinforcement of yellow and bright-
ness, followed by the integration of red [20].
Aerobic training (AT/CT)
Aerobic training is the actual gold-standard treatment for
CRF and was used in the control arm (AT) and in the
multimodal-aerobic combination therapy (CT). The aim
of this intervention was to achieve a 70–80% exposure in
order to improve the endurance and physical performance
and with this the global and physical fatigue [28]. At the
beginning, patients’ performance status was individually
evaluated by ergometry test with increasing steps by 25
watt every two minutes and heart rate being monitored at
the end of each step [29]. In the course of the trainer-
controlled therapy, performance adjustments were carried
out on the basis of heart rate monitor watches [29]. Eight
trainer-led 45-min sessions were carried out inclusive of a
rest period, which were complemented by home-based
training (3–5 × 30 – 45 min per week).
Outcome measures
Primary endpoint was a composite outcome of the Pitts-
burgh Sleep Quality Index (PSQI) and the Cancer Fatigue
Scale (CFS-D) after 10 weeks (T1); a second endpoint was
assessed after a follow-up period of 6 months (T2).
The German version of CFS-D is a 15-item scale with
three subscales (physical, cognitive and affective fatigue).
The CFS-D consists of a five-point Likert scale (0–4),
with its global scale ranging from 0 (no fatigue) to 60
(maximum fatigue). The CFS was developed in Japan
[30], and validated in German as the CFS-D [31]. The
CFS-D is highly reliable (Cronbach’s-alpha rα = 0.94,
test-retest reliability rrt = 0.82) with a robust validity [31]
and classifies values ≥ 30 as clear symptoms of fatigue, ≥
24 points as suspected moderate fatigue and ≤ 23 as no
or only minor symptoms.
The PSQI is a widely used questionnaire which cap-
tures sleep quality and attitudes. Along with qualitative
items, the scale consists of 18 quantitative items split
into seven components with values ranging from 0 to 3
(sleep quality, sleep latency, sleep duration, sleep effi-
ciency, sleep disturbances, use of hypnotics, and daily
sleepiness). The overall sum-scale detects the global
sleep quality ranging from 0 (good sleep quality) to 21
(maximum sleep disturbances) [32].
Safety
At each intervention, any subjective health complaints
reported by patients were recorded independent of a
possible relation to the study interventions and graded
according to the Common Toxicity Criteria for Adverse
Events. Incidences representing serious adverse events




To avoid multiple testing inflation of the alpha error the
analysis included two provisions, the combination of
CFS-D and PSQI into an univariate composite score de-
rived from their joint principal component (PC-score)
[33], and the use of a closed testing procedure [34]. The
comparison of the treatments started with a combined
Fig. 1 Overview of the study design
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test for superiority of CT and for non-inferiority of MT
compared to AT. Only if this overall test was statistically
significant could the separate comparisons of CT and
MT to AT be evaluated in a confirmative intention.
Sample-size estimation
For the comparison between CT and AT the smallest clin-
ically relevant difference, i.e., 5% of the respective param-
eter range, was assumed for both outcome measures [35].
Standardized effect sizes (Cohen’s d) were calculated using
standard deviations derived from the pilot study [19].
Sample size estimation was based on the combined test
for superiority of CT and for non-inferiority of MT com-
pared to AT. As non-inferiority thresholds (δ) a uniform
standardized effect size of δ = 0.2 was chosen for both
CFS-D and PSQI due to medical and statistical reasons.
Since no sample size formula for Läuter’s PC-score exists,
a marginal modeling approach for correlated parameters
based on general estimation equations was used [36]. Fur-
ther estimations were done by simulation using random
datasets. The most conservative estimation yielded a total
sample size of 114 patients.
Statistical analysis
According to the primary hypotheses of this study a) CT
is superior to AT, and b) MT is at least as effective as
AT in improving the composite endpoint of CFS-D and
PSQI after 10 weeks of intervention. The general linear
model used for testing both hypotheses included the
PC-score at T1 as dependent variable, the baseline PC-
score at T0 as covariate, and the treatment arm and
preference/randomization status as independent factors.
Since preference for a certain treatment may result in a
biased outcome two propensity scores (PS) were add-
itionally included in the model as continuous covariates
aiming to account for a) treatment allocation by prefer-
ence versus randomization, and b) preferring AT over
MT, respectively. The logistic regression models for cal-
culating the PS included age and vital signs, anamnestic
and socio-demographic parameters, baseline values of
the efficacy parameters, and questionnaires regarding
patients’ expectations, autonomic and self-regulation
[37]. Exploratory analyses assessed the PC-score at T2 as
well as the CFS-D and PSQI and their respective sub-
scales separately at T1 and T2. Changes from baseline
are descriptively expressed as standardized effect sizes to
enable a direct comparison of all parameters [38].
All analyses were based on the intention-to-treat
principle, i.e., including all patients with valid screening/
baseline measurements at T0. Missing questionnaire items
were substituted according to their respective manuals.
For the primary effectiveness analysis missing data at T1
were imputed by last-value-carried-forward (LOCF) as
provided for in the protocol. Sensitivity analyses were
done using worst-case and multiple imputations of miss-
ing data, omitting PS from the model, and using PS values
derived from various models. PS never showed a signifi-
cant influence, and even the restricted model without PS
gave an equivalent outcome (results not shown).
Adverse events were analyzed with respect to the ab-
solute number of affected patients and frequency of inci-
dences. Only treatment-emergent signs and symptoms
(TESS, i.e., between start of treatment and 4 weeks after
last therapy visit) were further examined. Relative fre-
quencies were calculated with reference to a single appli-
cation and to the total length of patients’ therapy
periods. Treatment groups were compared with regards
to relative frequency and severity of TESS using a Pois-
son model accounting for differences in patients’ treat-
ment durations.
All tests were carried out two-sided at an alpha error
level of α = 5% and with corresponding 95% confidence
intervals. Randomization lists, sample size estimates and
statistical analyses were produced using SAS® version 9.1
(SAS® Institute, Cary, NC, USA).
Results
Between June 2011 and March 2013 278 breast cancer
patients were referred to the study physicians for screen-
ing. Of these, 132 breast cancer patients with a signifi-
cant chronic cancer-related fatigue were assessed for
eligibility and from these 126 were included in the study
(65 randomized and 61 assigned by preference; Fig. 2).
28, 44 and 54 patients were randomly allocated to/ pre-
ferred the aerobic (AT: 22/ 6), multimodal (MT: 21/ 23)
and combination arm (CT: 22/ 32), respectively. 20 pa-
tients who did not participate in the baseline assessment
or any intervention were excluded from the Intention-
to-Treat analysis (ITT). One AT patient had to be ex-
cluded before intervention due to an activated arthrosis.
Of the remaining 105 patients included in the ITT
analysis, 84 finished the intervention (13/ 30/ 41), and
81 patients (13/ 28/ 40) completed the 6-month (T2)
follow-up. (Fig. 2: Flow chart).
Study-group characteristics
Patients’ mean age ranged from 56.4 to 58.8 without show-
ing significant differences between intervention groups.
Similarly, the study arms were comparable with regard to
time since first diagnosis, tumor biology, stage and treat-
ment, or to socio-demographic characteristics (Table 2) ex-
cept of a smaller average height in the AT-group (163 cm
compared to 168 cm and 167 cm in the CT and MTgroup,
respectively; p = 0.0168), less HADS-anxiety (MT: mean =
7.3 (SD = 3.1); AT: mean = 9.4 (4.3); CT: mean = 9.3 (3.5);
p = 0.0263), less rehabilitation (MT= 11.76%; AT = 35%;
CT = 31.37%; p = 0.027) and ‘other disorders’ (p = 0.0313)
in the MT group compared to AT and CT. Nevertheless,
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baseline values of CFS-D and PSQI were comparable
(Table 3). The factors most prominently contributing to
the PS regarding randomization or preference included
patients’ ‘expectations to better cope with daily life and
deal with the disease’, actual hormonal therapy, concomi-
tant medication, diastolic blood pressure, participation in
rehabilitation programs, and the score of the questionnaire
on self-regulation [39]. Factors mostly contributing to the
PS regarding the preference for MT over AT included
tumor stage, actual tumor aftercare, vocational training,
and patients’ expectation of a better physical condition.
AT consisted of trainer-guided treatment of 360 min.
Home-based training was on average practiced for
223 min/ week (SD = 179) which corresponds to a low-
level adherence exercise rate of 67% (3 × 30 min/ week).
The intervention program of the CT group comprised
1810 min. In the home-based exercise training the CT
patients practiced on average for 155 min/ week (low-
Fig. 2 Flow chart for recruitment
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Table 2 Socio-demographic characteristics at baseline
Treatment group Aerobic treatment Multimodal treatment Combination treatment p-value
Included 28 44 54
Started Intervention T0 20 34 51
Completed T1 13 30 41
Marital status
Single (%) 1 (5.00) 7 (20.59) 8 (15.69) 0.5994
Married (%) 14 (70.00) 16 (47.06) 27 (52.94)
Divorced (%) 3 (15.00) 8 (23.53) 13 (25.49)
Widowed (%) 2 (10.00) 2 (5.88) 2 (3.92)
Missing data (%) 0 (0.00) 1 (2.94) 1 (1.96)
Children: yes (%)/ Children at home: yes (%) 16 (80.00)/ 6 (30.00) 23 (67.65)/ 8 (23.53) 38 (74.51)/ 11 (21.57) 0.3481/ 0.6599
Employment
Employed (%) 9 (45.00) 10 (29.41) 25 (49.02) 0.1242
Housewife (%) 1 (5.00) 3 (8.82) 1 (1.96)
Unemployed (%) 0 (0.00) 1 (2.94) 6 (11.76)
Pensioner (%) 6 (30.00) 13 (38.24) 11 (21.57)
Sickness certificate (%) 3 (15.00) 4 (11.76) 4 (7.84)
Other (%) 0 (0.00) 2 (5.88) 1 (1.96)
Missing data (%) 1 (5.00) 1 (2.94) 3 (5.88)
Vocational education
Apprenticeship (%) 9 (45.00) 13 (38.24) 20 (39.22) 0.2138
Technical College (%) 4 (20.00) 3 (8.82) 3 (5.88)
University of Applied Sciences (%) 3 (15.00) 2 (5.88) 4 (7.84)
University (%) 0 (0,00) 9 (26.47) 12 (23.53)
No (%) 0 (0.00) 1 (2.94) 1 (1.96)
Missing data (%) 4 (20.00) 6 (17.65) 11 (21.57)
Age: Mean (SD) 59.8 (9.8) 60.3 (9.5) 56.6 (7.9) 0.1460
Years since first diagnosis: Mean (SD) 1.9 (0.9) 2.2 (0.8) 1.9 (0.8) 0.1273
Surgery: yes/ % 20/ 100.0 34/ 100.0 51/ 100.0
Chemotherapy: yes/ % 12/ 60.00 22/ 64.71 19/ 37.25 0.0501
Years since chemotherapy: Mean (SD) 2.1 (0.7) 1.6 (0.6) 1.8 (0.7) 0.1372
Radiotherapy: yes/ % 14/ 70.00 29/ 85.29 38/ 74.51 0.6000
Antihormonal therapy: yes/ % 17/ 85.00 23/ 67.65 32/ 62.75 0.4947
Mistletoe therapy: yes/ % 6/ 30.00 7/ 20.59 13/ 25.49 0.6797
Numbers and percentages concerning patients which started the intervention (T0)
Table 3 Baseline values of Cancer Fatigue Scale (CFS-D) and Pittsburgh Sleep Quality Index (PSQI)
Aerobic therapy Multimodal therapy Combination therapy p-value
CFS-D total score
Baseline 33.5 (8.8) 33.0 (7.7) 34.3 (8.1) 0.6065
PSQI total score
Baseline 10.0 (3.5) 10.9 (3.5) 10.3 (3.9) 0.5489
Mean (SD)
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level exercise rate of 52.3%), and home-based eurythmy
therapy for ten minutes over 6.4 days/ week. The MT
group was invited to participate in a 1450-min program.
Here, the minimal home-based eurythmy practice of ten
minutes was documented on average in 6.5 days/ week.
The standardized effect sizes of the primary outcome
in the AT, MT and CT group for change from baseline
to T1 were 0.48, 1.11, and 0.92; and 0.24, 1.06, and 0.96,
for the change from baseline to T2 (Fig. 3), respectively.
In the closed testing procedure the global null hypoth-
esis of no overall effect at T1 regarding superiority of
CT and non-inferiority of MT versus AT could signifi-
cantly be rejected (df = 2; F = 4.68; p = 0.0115). Similarly,
in the subsequent pair-wise comparison MT could be
shown to be non-inferior to AT (with regard to the non-
inferiority threshold δ) (ΔPC incl. δ = −0.0476, 95%-CI
[−0.0812; −0.0140]; p = 0.0059). However, superiority of
CT over AT could not be demonstrated (ΔPC = −0.0247,
95%-CI [−0.0558; 0.0064]; p = 0.1187). Hence, the con-
firmatory analysis was terminated and all subsequent
tests were carried out with an explorative intention.
Here, even a significant improvement over AT could be
shown for the MT group (ΔPC = −0.0369, 95%-CI
[−0.0705; -0.0034]; p = 0.0314). At T2, 6 months after
the intervention, both MT and CT were significantly su-
perior to AT (CT vs. AT: ΔPC = −0.0436, 95%-CI
[−0.0781; −0.0091]; p = 0.0137; MT vs. AT: ΔPC =
−0.0538, 95%-CI [−0.0910; −0.0166]; p = 0.0050) (Fig. 3).
The standardized effect sizes of the CFS-D in the AT,
MT and CT group for the change from baseline to T1
were 0.72, 1.16, and 0.98, respectively; and 0.39, 1.18,
and 0.90 for T2, respectively. For the PSQI, the corre-
sponding effect sizes values for T1 were 0.29, 0.83, and
0.64, respectively; and 0.09, 0.69, and 0.79 for T2, re-
spectively. In separate analyses of CFS-D and PSQI the
MT group at both time points T1 and T2 demonstrated
a superior effectiveness over AT (except for CFS-D at
T1 where only non-inferiority could be shown), whereas
for CT no statistical superiority over AT could be
shown with the exception of PSQI at T2 (Table 4). In
further differentiated analyses of the questionnaire
subscales the MT groups showed the strongest effects
in the CFS-D subscales, statistically superior to AT
for affective (at T1 and T2) and physical fatigue (T2)
and non-inferior for cognitive fatigue (T1, T2). For
the CT group strong and significant improvements
over AT were observed at T2 for the PSQI subscales
‘subjective sleep quality’, ‘sleep latency’, and ‘sleep dur-
ation’. Regarding the PSQI subscales, for MT only for
‘sleep latency’ at T1 and ‘daytime sleepiness’ at T2
significant differences to AT were found. In no
parameter and at no time point was AT statistically
superior to any of the experimental treatment arms,
and only once (PSQI ‘sleep duration’) was the mean
AT value marginally better compared to MT and CT
(Table 4).
Fig. 3 Presentation of the combined outcome (PC-score) of fatigue (CFS-D)/sleep quality (PSQI) at baseline (T0), after 10 weeks intervention (T1)
and 6 months later (T2). High values show high fatigue burden and sleep disturbances. The colored asterisk indicates significantly reduced fatigue/
sleep disturbances. Red solid line: AT; blue dashed-dotted line: MT; purple dashed line: CT. Higher PC-scores refer to worse complaints
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Safety
Over the course of the entire study period 115 adverse
events (AEs) were documented, 87 of which were TESS.
Five TESS were classified as adverse therapy reactions
with an at least possible causal connection to one of the
study interventions: ‘back pain’, reported once in each of
the treatment groups; ‘dizziness during eurythmy’; and
‘increasing exhaustion through sleep restriction/stimulus
control’, both occurring in the MT group. With regard to
individual interventions, all adverse therapy reactions
occurred ‘very rarely’ (<0.01%) to ‘rarely’ (0.01–0.1%)
except of ‘pain’ in the AT group which occurred
Table 4 Differences from baseline values at T1 and T2
Aerobic therapy Multimodal therapy p Combination therapy p
CFS-D total score
T1.10-T0.01 −6.3 (7.4) −8.9 (7.1)† 0.053 −7.9 (9.0) 0.285
T2-T0.01 −3.4 (9.1) −9.1 (7.9)†† 0.004 −7.3 (10.2) 0.111
PSQI total score
T1.10-T0.01 −1.0 (1.8) −2.9 (2.9)†† 0.044 −2.5 (3.4) 0.077
T2-T0.01 −0.3 (2.8) −2.4 (4.0)† 0.047 −3.1 (3.2) 0.007
CFS-D physical
T1.10-T0.01 −3.2 (3.8) −3.7 (3.5) 0.359 −3.2 (4.2) 0.777
T2-T0.01 −0.9 (4.1) −4.1 (4.2)†† 0.003 −3.1 (4.6) 0.075
CFS-D cognitive
T1.10-T0.01 −2.0 (2.3) −3.0 (3.1)† 0.062 −2.5 (3.1) 0.556
T2-T0.01 −2.0 (3.6) −2.9 (3.2)† 0.055 −2.6 (3.7) 0.431
CFS-D affective
T1.10-T0.01 −1.1 (1.9) −2.2 (2.0)†† 0.004 −2.2 (2.6) 0.018
T2-T0.01 −0.5 (2.1) −2.2 (1.7)††† 0.004 −1.6 (3.4) 0.079
PSQI subjective sleep quality
T1.10-T0.01 −0.5 (0.5) −0.6 (0.6) 0.842 −0.5 (0.8) 0.757
T2-T0.01 −0.1 (0.7) −0.6 (0.8)† 0.054 −0.7 (0.7) 0.041
PSQI sleep latency
T1.10-T0.01 0.0 (0.8) −0.7 (0.9)†† 0.004 −0.3 (0.8) 0.066
T2-T0.01 0.1 (0.8) −0.4 (1.0) 0.155 −0.4 (1.1) 0.0296
PSQI sleep duration
T1.10-T0.01 −0.5 (0.7) −0.2 (0.8) 0.497 −0.2 (1.0) 0.517
T2-T0.01 −0.1 (0.6) −0.4 (1.2) 0.226 −0.6 (1.1) 0.036
PSQI sleep efficiency
T1.10-T0.01 −0.3 (0.8) −0.7 (1.3) 0.258 −0.6 (1.1) 0.335
T2-T0.01 0.1 (1.0) −0.3 (1.3) 0.759 −0.7 (1.1) 0.0597
PSQI sleep disturbances
T1.10-T0.01 −0.1 (0.3) −0.3 (0.6) 0.411 −0.2 (0.6) 0.463
T2-T0.01 −0.1 (0.6) −0.3 (0.6) 0.2497 −0.1 (0.7) 0.397
PSQI taking hypnotics
T1.10-T0.01 0.3 (0.9) −0.1 (0.5)† 0.109 −0.1 (0.6) 0.109
T2-T0.01 −0.1 (0.9) 0.1 (0.6) 0.398 −0.1 (0.6) 0.637
PSQI daytime sleepiness
T1.10-T0.01 −0.3 (0.8) −0.5 (0.7)† 0.066 −0.5 (0.6) 0.326
T2-T0.01 −0.2 (0.7) −0.5 (0.8)†† 0.024 −0.5 (0.8) 0.180
p-value for test for superiority vs. aerobic therapy
†test for non-inferiority vs. aerobic therapy
Mean (SD); †p < 0.05, ††p < 0.01; †††p < 0.001
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‘occasionally’ (0.1–1%). In relation to total intervention
time, AEs not related to study treatments occurred less
frequently in the MT group (MT: 0.035/ week, 95%-CI
[0.018; 0.067]; AT: 0.054/ week, 95%-CI [0.025; 0.1198];
CT: 0.080/ week, 95%-CI [0.056; 0.113]; compared to CT
this difference is significant (p = 0.0229). Moreover, 47
and 15% of all TESS in the CT group were of a medium
and severe nature, respectively, while these frequencies
in the MT group were only 13 and 6%, respectively; in
the AT group intermediate frequencies of 27 and 9%
were observed, respectively.
Discussion
This is the first effectiveness study that evaluates the re-
cently developed multimodal concept consisting of psy-
cho- and sleep-education and mindfulness-based
eurythmy- and art therapy [20]. In the confirmatory test
procedure the multimodal therapy was formally non-
inferior and in combination with aerobic training not
superior to AT in reducing fatigue/disturbed sleep com-
pared to standard aerobic training after 10 weeks,
whereas in our explorative analyses, we found a signifi-
cant reduction in the MT group at T1 and in both
experimental groups 6 months later, with strong effect-
sizes both in MT and in CT. Both scales of the PC-score
of CFS-D and PSQI contributed in a comparable man-
ner to the therapeutic effects. While in the MT arm
improvements were mainly based on the affective and
physical subscales of the CFS-D and the daytime sleepi-
ness scale of the PSQI, in the CT arm several subscales
of the PSQI (‘subjective sleep quality’, ‘sleep latency’, and
‘sleep duration’) contributed preferentially to the ob-
served improvement at T2.
The presented effects are higher than the minor to
moderate effect sizes from standard endurance training,
cognitive behavioral therapy [40], and mindfulness-
orientated yoga [41] or mindfulness-based stress reduc-
tion [42], and point therefore to synergistic sustainable
effects on sleep quality and CRF. Corresponding to the
increasing evidence of the relationship between CRF and
sleep, a pathophysiological model of CRF focuses on the
interaction of chronic inflammation, sleep disorder, dis-
rupted rhythm, neuroendocrine disturbances such as
cortisol rhythm flattening or reduced responsiveness of
cortisol to stress and consecutive central nervous system
dysregulations such as elevated corticotropin-releasing
hormone, reduced growth factor or 5-Hydroxytryptamin
on CRF, cognitive dysfunction, impaired sleep or depres-
sion [43]. In breast and lung cancer patients, a polysom-
nography study reports a reduced sleep-efficiency, more
wake-after-sleep-onset compared to healthy control and
body movements compared to patients with psycho-
physiological insomnia, underlining the non-restorative
sleep in these patients [44]. Even if a small study of
breast cancer patients undergoing chemotherapy found
no other physiological changes in polysomnography
apart from an increase in fatigue, prolongation of total
sleep time and a persistent unchanged low-level slow
wave sleep [45], in different studies subjective and acti-
graphic sleep-quality decline significantly under chemo-
therapy [46].
As a conclusion, these aspects underline firstly the com-
plexity of CRF and secondly the weak to moderate effects
of actual evidence-based individual treatments, which im-
plicate that a multimodal approach such as implemented as
standard therapy in chronic pain management [47] could
be an adequate concept. Even though a multimodal mind-
body based intervention program consisting of nutrition
counseling, relaxation exercises, physical exercises, stress
reduction, basics of cognitive restructuring and hydrother-
apy did not show superiority in breast cancer survivors with
CRF compared to aerobic training [17] we decided to im-
plement our program with a stronger focus on sleep resyn-
chronization and cancer-specific psycho-education [20].
Our hypothesis is that sleep education, restriction, and
stimulus control together with the other treatment compo-
nents improve PSQI-sleep quality in reducing sleep onset
latency, sleep duration, and improvement of sleep continu-
ity. Based on the reduced sleep de-synchronization, daytime
sleepiness and fatigue can improve. This is consistent with
the results of two randomized controlled trials (RCTs) in
breast cancer patients with CRF [10, 11] showing clear im-
provements of sleep quality, but fewer effects on CRF. In
our study, however, PSQI-sleep quality and CFS-D fatigue
contribute equally to the composite PC-score. This finding
points to different effecting mechanisms. Along with the
stabilization of the rest/activity rhythm we wanted to
strengthen patients’ self-management and self-regulation
with the help of psycho-education, and patients’ active
stress-management competence with an impact on
(affective) CRF [20] with the practice of mindfulness-
oriented eurythmy and painting therapy. For mindfulness-
based stress reduction and yoga, small effect sizes in CRF
have been published [41] with a first indication of concomi-
tant reduction in inflammation-related gene expression
[48]. Even though no CRF-related trial has been conducted
for eurythmy therapy there are first indications that it can
have a stress-reducing [49], and a heart-rate variability- and
rhythm stabilizing effect [50]. For painting- or art-therapy a
review found positive effects on health-related quality of
life, depressive and anxiety symptoms and, in qualitative
studies, hints for personal development [51]. Hence, we in-
terpret the strong effect size in the multimodal treatment
group as synergistic effects of the different treatment
components, although their distinct contribution remains
unclear. The reduced and delayed therapy effects in the
combined group could be related to the increased fre-
quency and the severity of unspecific side effects. With the
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combination therapy, the higher risk of these unspecific
side effects could be related to endurance training as well
as to ‘over-stimulation’. Based on the low-level of TESS all
evaluated therapies are well tolerated and can be regarded
as very safe. Nevertheless, the intensity of aerobic training
should be reduced in the combination therapy. Even if the
efficacy of the multimodal approach needs still to be
proven in another trial two positive studies strongly sup-
port its sustainable effects [20].
Adverse events in general were rarely documented,
and only exceptionally regarded as related to any
study intervention. However, the relative higher fre-
quency and severity of AEs in the CT arm, statisti-
cally detectable when compared to MT, indicates that
there might have been an excessive demand regarding
the physical capabilities at least in some of these pa-
tients. Together with the impression that treatment
effects seem in general to be less pronounced in the
CT arm compared with MT this raises questions
regarding the appropriate amounts of multimodal
therapy and aerobic training for optimal CT.
The inclusion criteria strictly concentrated on patients
with CRF, but the exclusion of metastasized breast cancer
patients in particular may limit the generalization of the
results. Our study has some other limitations such as the
small sample size and relatively high drop-out rate in the
preference aerobic arm. Replacement of so high a percent-
age of missing data by last-value-carried-forward can
introduce a strong bias. Yet, it is our impression that pa-
tients did not drop out randomly but due to dissatisfaction
or overstraining with regard to the therapies. In this case
last-value-carried-forward replacement, which means ‘no
change from baseline’, is a justifiable approach as could be
confirmed in an inspection of individual patient measure-
ments. Another concern is that the patients in the aerobic
standard therapy group received a shorter, trainer-guided
treatment of 360 min compared to the combined- and
multimodal treatment arms. This could be understood
and discussed in the sense of receiving less attention.
Nevertheless, the therapeutic effect sizes both at T1 and
T2 are beyond or in the range of other published meta-
analyses in breast cancer survivors [9, 52, 53]. Although
the overall drop-out rate of 20% is high, it is within the
range of other endurance training studies [54]. The four-
fold respective five-fold longer intervention time of
the multimodal- and combined treatment are related
to corresponding higher costs of therapists. Finally,
the principal distinction between patients actively
pursuing a certain therapy and patients passively ran-
domized into this therapy could introduce not only
bias but, at worst, a negative interaction between allo-
cation regime and treatment. No such interaction was
observed, yet a detailed examination and publication
of these conditions is in preparation.
Conclusions
The presented study indicates non-inferiority and, based
on exploratory results, superiority of a multimodal ap-
proach in the treatment of chronic cancer-related fatigue
compared to the standard aerobic therapy. This suggests
that a multimodal therapy concept consisting of move-
ment therapy, behavior- and mindfulness-based therapies
might have the potential to become standard treatment.
Therefore a further confirmative RCT is indicated which
should investigate the long-term outcome alongside cost-
effectiveness.
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